AAA617
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Oligometastatic Prostate Cancer (OMPC)
Conditions
Oligometastatic Prostate Cancer (OMPC)
Trial Timeline
Mar 12, 2024 → Oct 3, 2031
NCT ID
NCT05939414About AAA617
AAA617 is a phase 3 stage product being developed by Novartis for Oligometastatic Prostate Cancer (OMPC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05939414. Target conditions include Oligometastatic Prostate Cancer (OMPC).
What happened to similar drugs?
0 of 1 similar drugs in Oligometastatic Prostate Cancer (OMPC) were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05939414 | Phase 3 | Recruiting |
| NCT05803941 | Approved | Recruiting |
Competing Products
5 competing products in Oligometastatic Prostate Cancer (OMPC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lutetium Lu-177 PNT2002 | Eli Lilly | Phase 2 | 39 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 3 | 47 |
| Actinium Ac 225 Vipivotide Tetraxetan + Lutetium Lu 177 Vipivotide Tetraxetan | Novartis | Phase 2 | 42 |
| Quemliclustat + Etrumadenant + Zimberelimab | Arcus Biosciences | Phase 2 | 36 |